Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.

Abstract

INTRODUCTION:

Osteopontin (OPN) is a malignancy-associated glycoprotein that contributes functionally to tumor aggressiveness. In metastatic breast cancer, we previously demonstrated that elevated OPN in primary tumor and blood was associated with poor prognosis.

METHODS:

We measured OPN in plasma by ELISA, and in tumors by immunohistochemistry, in 624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/- octreotide in a randomized trial (NCIC CTG MA.14; National Cancer Institute of Canada Clinical Trials Group Mammary.14).

RESULTS:

Plasma OPN was measured in 2,540 samples; 688 at baseline and 1,852 collected during follow-up. Mean baseline plasma OPN was 46 ng/ml (range 22.6 to 290) which did not differ from normal levels. Mean percentage OPN tumor cell positivity was 33.9 (95% CI: 30.2 to 37.9). There was no correlation between plasma and tumor OPN values. In multivariate analysis, neither was associated with event-free survival (EFS), relapse-free survival (RFS), overall survival (OS), bone RFS or non-bone RFS. An exploratory analysis in patients with recurrence showed higher mean OPN plasma levels 60.7 ng/ml (23.9 to 543) in the recurrence period compared with baseline levels.

CONCLUSIONS:

The hypothesis that OPN tumor expression would have independent prognostic value in early breast cancer was not supported by multivariate analysis of this study population. Plasma OPN levels in women with hormone responsive early breast cancer in the MA.14 trial were not elevated and there was no evidence for prognostic value of plasma OPN in this defined group of patients. However, our finding of elevated mean OPN plasma level around the time of recurrence warrants further study.

TRIAL REGISTRATION:

NCT00002864, http://clinicaltrials.gov/show/NCT00002864.

• Authors: Vivien H C Bramwell, Alan B Tuck, Judith-Anne W Chapman, Pieter H Anborgh, Carl O Postenka, Waleed Al-Katib, Lois E Shepherd, Lei Han, Carolyn F Wilson, Kathleen I Pritchard, Michael N Pollak, Ann F Chambers
• Journal: Breast cancer research : BCR (Breast Cancer Res) Vol. 16 Issue 1 Pg. R8 (Jan 22 2014) ISSN: 1465-542X [Electronic] England
• PMID: 24451146 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Hormonal
• Biomarkers, Tumor
• Tamoxifen
• Osteopontin
• Octreotide

Topics

• Antineoplastic Agents, Hormonal (therapeutic use)
• Biomarkers, Tumor (blood)
• Breast Neoplasms (blood, drug therapy, surgery)
• Disease-Free Survival
• Female
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (blood)
• Octreotide (therapeutic use)
• Osteopontin (blood)
• Tamoxifen (therapeutic use)